Indianapolis-based FAST Diagnostics gets funding from BioCrossroads’ seed fund
Money will help the company refine its tool to treat acute kidney injury.
Life Science & Biotech
Articles
Dow AgroSciences’ revenue, profit fall on lower crop prices
Dow AgroSciences, the local subsidiary of Midland, Mich.-based Dow Chemical Co., said Thursday that revenue fell 20 percent
and profits plummeted in the third quarter due largely to lower crop commodity prices.
Zimmer profits fall, but beat expectations
The Warsaw-based company recorded a third-quarter profit of $150 million, down 30 percent from the same quarter a year ago.
Cook: Tax could kill 1,000 jobs in Bloomington
Bloomington-based Cook Group Inc. could find itself cutting as many as 1,000 local jobs if Congress enacts a tax on
medical devices to pay for health care reform, company founder Bill Cook said in an interview.
State’s health IT groups seek stimulus funds
Some of Indiana’s leading organizations in health information technology are collaborating on an effort to receive several
million dollars of stimulus funding.
Purdue gets $1M for plant-climate research
The U.S. Department of Agriculture has given Purdue University a nearly $1 million grant to study ways that genomics can be
used to enhance the value of certain plants while making them more resilient to climate stress.
Dow AgroSciences ratcheting up biotech efforts
Dow AgroSciences’ introduction of a promising new product is helping transform the Indianapolis company as it transitions
from a focus on traditional agricultural chemicals to genetically altered seeds. The subsidiary of Michigan-based Dow Chemical
Co. partnered with St. Louis-based Monsanto Co. to develop what could become its biggest blockbuster, a genetically modified
corn variety it calls SmartStax.
Indiana life sciences leaders discover dozens of tiny outsourcing companies
BioCrossroads, an Indianapolis-based not-for-profit, is cataloging Indiana businesses offering contract services to pharmaceutical
and biotechnology companies, and discovering many small firms operating in relative obscurity.
Dow AgroSciences and the Holy Grail
Dow AgroSciences could boost its market share in genetically altered corn almost overnight by inventing a perennial corn.
But investors might not have the patience.
Dow Agro to become Purdue research tenant
Officials of Purdue University and Dow AgroSciences unveiled a collaboration Wednesday in which the Indianapolis-based company
will become one of the largest tenants at the Purdue Research Park in West Lafayette.
Lilly’s win in Evista patent case crucial, analyst says
A decision by a federal judge in Indianapolis to turn back a patent challenge to Eli Lilly and Co.’s Evista marks a major
victory for the company, says an analyst who closely follows the pharmaceutical industry.
Judge upholds Lilly’s Evista patent
A federal judge in Indianapolis turned back a patent challenge to Eli Lilly and Co.’s drug Evista, the company announced
late yesterday.
Lilly Endowment funds OrthoWorx effort with $7 million
A new group expected to develop the orthopedic implants industry in Warsaw will be able to proceed now that Indianapolis-based
Lilly Endowment Inc. is putting $7 million behind it, according to an announcement this morning.
Lilly sells constipation drug to Adolor
Biotechnology company Adolor Corp. said yesterday that it bought exclusive worldwide rights to Eli Lilly and Co.’s OpRA
III drug candidate, which has a range of potential uses.
Lilly: Alimta improves lung-cancer survival time
Indianapolis-based Eli Lilly and Co. announced today that a clinical trial showed lung cancer patients treated with Lilly
drug Alimta lived about three months longer than those who received the best available care.
A beachhead in Warsaw
The launch of the orthopedics not-for-profit OrthoWorx is quite an accomplishment in Warsaw, where some of the world’s
biggest companies fight tooth-and-nail.
Lilly reorganization to cut 5,500 positions over 2 years
Eli Lilly and Co. will cut 5,500 jobs by the end of 2011 as it tries to cut $1 billion in expenses before it loses revenue
from its bestselling drug, Zyprexa. Lilly CEO John Lechleiter said he did not know how many of those cuts would occur in central
Indiana. But with
13,600 employees working in the Indianapolis area, he acknowledged the largest chunk of reductions likely would come here.
Medical device developer receives $1M in federal funding
Indianapolis-based FAST Diagnostics, a developer of a method to quickly measure kidney function, announced today that it has
received $1 million in federal funding.
BioCrossroads rolls out orthopedic initiative
With job growth surging in Warsaw’s orthopedic cluster, the life sciences development group BioCrossroads Inc. set out to…
Sweetener company Heartland looks for openings in crowded field
Heartland Sweeteners LLC is now a top maker of private-label alternatives to Splenda. The company also
markets its own products directly to consumers.